Rifamycin AF
Product Code: AG-CN2-0321
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0321-G001 | 1 g | £75.00 |
Quantity:
| AG-CN2-0321-G005 | 5 g | £270.00 |
Quantity:
| AG-CN2-0321-G010 | 10 g | £490.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NCI 145-635; 3-Formylrifamycin; 3-Formylrifampicin SV; 3-Formylrifamycin SV; Rifaldehyde
Appearance:
Red powder.
CAS:
13292-22-3
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light.Protect from light when in solution.
Hazards:
H319
InChi:
InChI=1S/C38H47NO13/c1-16-11-10-12-17(2)37(48)39-28-23(15-40)32(45)25-26(33(28)46)31(44)21(6)35-27(25)36(47)38(8,52-35)50-14-13-24(49-9)18(3)34(51-22(7)41)20(5)30(43)19(4)29(16)42/h10-16,18-20,24,29-30,34,42-46H,1-9H3,(H,39,48)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,24?,29-,30+,34+,38-/m0/s1
InChiKey:
BBNQHOMJRFAQBN-LXFNAIAASA-N
Long Description:
Chemical. CAS: 13292-22-3. Formula: C38H47NO13. MW: 725.8. Semisynthetic. Ansamycin antibiotic. Intermediate of rifampicin. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria, and are therefore used in research of tuberculosis, leprosy and mycobacterium avium complex (MAC) infections.
MDL:
MFCD01729454
Molecular Formula:
C38H47NO13
Molecular Weight:
725.8
Package Type:
Vial
Precautions:
P305+P351+P338
Product Description:
Ansamycin antibiotic. Intermediate of rifampicin. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria and therefore used in research of tuberculosis, leprosy and Mycobacterium avium complex (MAC) infections.
Purity:
>95% (HPLC)
Signal word:
Warning
SMILES:
OC1=C(NC(/C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@H]([C@@H](C)[C@@H]([C@H](C)[C@H](/C=C/O2)OC)OC(C)=O)O)=O)C(C([H])=O)=C(O)C3=C4C(O[C@@]2(C)C4=O)=C(C)C(O)=C31
Solubility Chemicals:
Soluble in DMSO, aqueous acetonitrile or ethanol.
Source / Host:
Semisynthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Rifamycins: A General View: S. Riva & L.G. Silvestri; Ann. Rev. Microbiol. 26, 199 (1972) | Spin-labeled rifamycin: biological activity: Z.Z. Raykov, et al.; Pharmazie 63, 61 (2008) | New anti-tuberculosis agents amongst known drugs: K.A.E. Lougheed, et al.; Tuberculosis 89, 364 (2009) | The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis: P. Przybylski, et al.; Bioorg. Med. Chem. Lett. 25, 3903 (2015) | Rifamycin antibiotics - new compounds and synthetic methods. Part 4: Study of the reaction of 3-formylrifamycin SV with secondary amines and ketones: K. Bujnowski, et al.; Tetrahedr. 71, 158 (2015)
Related Products
| Product Name | Product Code | Supplier | Rifamycin AF-API | AG-CN2-0325 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifamycin AF-EPTAPI | AG-CN2-0326 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-DA | AG-CN2-0328 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AG | AG-CN2-0329 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||